NASDAQ:EGRX Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis $4.25 -0.14 (-3.19%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.13▼$4.4150-Day Range$3.87▼$6.0752-Week Range$3.21▼$17.32Volume55,861 shsAverage Volume180,847 shsMarket Capitalization$55.19 millionP/E Ratio3.60Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Eagle Pharmaceuticals alerts: Email Address Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Read More EGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EGRX Stock News HeadlinesSeptember 2, 2024 | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.comAugust 27, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 22, 2024 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqApril 30, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual MeetingApril 15, 2024 | globenewswire.comEagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, FloridaApril 14, 2024 | investing.comEagle Pharmaceuticals faces potential Nasdaq delistingSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 13, 2024 | msn.comStocks Slightly Higher as US Mar PPI Climbs Less Than ExpectedApril 13, 2024 | msn.comStocks Mixed as Bond Yields ClimbApril 12, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KFebruary 29, 2024 | msn.comEagle Pharmaceuticals to cut 36% of workforceFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and DatesFebruary 9, 2024 | prnewswire.comEAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their OptionsFebruary 8, 2024 | stockhouse.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)See More Headlines Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today9/07/2024Next Earnings (Estimated)9/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EGRX CUSIPN/A CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees100Year Founded2007Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio3.60 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$257.55 million Price / Sales0.21 Cash Flow$3.15 per share Price / Cash Flow1.35 Book Value$17.94 per share Price / Book0.24Miscellaneous Outstanding Shares12,987,000Free Float9,234,000Market Cap$55.19 million OptionableOptionable Beta0.51 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael Graves (Age 61)Interim Principal Executive Officer & Executive Chairman of the Board Comp: $160kMr. Steven B. Ratoff (Age 81)Interim CFO, Principal Accounting Officer & Director Comp: $100kMr. Daniel O'Connor (Age 44)Executive VP, Chief Strategy Officer & Head of Corporate Development Dr. Valentin R. Curt M.D.Senior Vice President of Clinical Drug DevelopmentDr. Gaozhong Zhu Ph.D.Senior Vice President of Pharmaceutical DevelopmentMs. Debra M. HussainSenior VP & Head of CommercialMr. Reed McClungExecutive Vice President of Oncology Business DevelopmentMore ExecutivesKey CompetitorsZIOPHARM OncologyNASDAQ:ZIOPSpectrum PharmaceuticalsNASDAQ:SPPIInhibrxNASDAQ:INBXTrevi TherapeuticsNASDAQ:TRVIZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 173,365 shares on 8/16/2024Ownership: 1.335%AQR Capital Management LLCSold 182,276 shares on 8/15/2024Ownership: 5.365%Point72 Asia Singapore Pte. Ltd.Bought 11,612 shares on 8/15/2024Ownership: 0.089%Mackenzie Financial CorpBought 10,786 shares on 8/15/2024Ownership: 0.083%Fidelis Capital Partners LLCBought 12,762 shares on 8/14/2024Ownership: 0.098%View All Insider TransactionsView All Institutional Transactions EGRX Stock Analysis - Frequently Asked Questions How have EGRX shares performed this year? Eagle Pharmaceuticals' stock was trading at $5.23 on January 1st, 2024. Since then, EGRX shares have decreased by 18.7% and is now trading at $4.25. View the best growth stocks for 2024 here. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) issued its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analysts' expectations of $46.70 million. Who are Eagle Pharmaceuticals' major shareholders? Eagle Pharmaceuticals' top institutional shareholders include AIGH Capital Management LLC (9.33%), AQR Capital Management LLC (5.37%), LSV Asset Management (2.27%) and Renaissance Technologies LLC (1.88%). Insiders that own company stock include Scott Tarriff and Richard A Edlin. View institutional ownership trends. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Recycling (RDUS) and bluebird bio (BLUE). This page (NASDAQ:EGRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
